Ivabradina Aurobindo

Ivabradine Hydrochloride, the active ingredient in Ivabradina Aurobindo, is an If channel inhibitor presented as an oral tablet for oral use. It reduces heart rate in patients with chronic stable angina pectoris and heart failure with reduced ejection fraction.

GNH USA supplies Ivabradina Aurobindo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ivabradina Aurobindo acts on the cardiac If current to manage conditions where heart‑rate reduction is therapeutic.

Chronic stable angina pectoris: improves exercise tolerance and decreases frequency of angina episodes. Heart failure with reduced ejection fraction: lowers heart rate and may improve functional status. Ischemic heart disease: helps control heart rate to reduce myocardial oxygen demand.

Adverse reactions have been reported with Ivabradina Aurobindo.

Common Side Effects: - Visual disturbances (phosphenes or luminous phenomena) - Bradycardia (heart rate <50 bpm) - Headache - Dizziness - Fatigue - Blurred vision

Serious or Rare Side Effects: - Severe bradycardia requiring medical intervention - Atrial fibrillation or other supraventricular arrhythmias - Symptomatic hypotension - Heart block or other conduction abnormalities

Use of Ivabradina Aurobindo requires careful clinical assessment. - Heart‑rate monitoring: check resting heart rate before initiation and periodically thereafter. - Severe hepatic impairment: avoid or use only with specialist guidance. - Sick sinus syndrome or atrioventricular block: contraindicated. - Concomitant bradycardic agents (e.g., beta‑blockers): dose adjustment may be needed. - Acute decompensated heart failure: do not initiate therapy. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Ivabradina Aurobindo may interact with several medicines.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole) – may markedly increase plasma levels. - Co‑administration with other bradycardic agents (e.g., beta‑blockers, digoxin) – risk of excessive heart‑rate reduction.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., erythromycin, clarithromycin) – may raise concentrations. - Calcium‑channel blockers that are CYP3A4 substrates (e.g., diltiazem, verapamil) – may increase exposure. - Antihypertensive agents – may enhance hypotensive effect.